Cargando…

The Evolution of Blood Cell Phenotypes, Intracellular and Plasma Cytokines and Morphological Changes in Critically Ill COVID-19 Patients

Background: Severe coronavirus disease 2019 (COVID-19) causes a strong inflammatory response. To obtain an overview of inflammatory mediators and effector cells, we studied 25 intensive-care-unit patients during the timeframe after off-label chloroquine treatment and before an introduction of immuno...

Descripción completa

Detalles Bibliográficos
Autores principales: Berghäll, Elisabeth, Hultström, Michael, Frithiof, Robert, Lipcsey, Miklos, Hahn-Strömberg, Victoria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9138896/
https://www.ncbi.nlm.nih.gov/pubmed/35625671
http://dx.doi.org/10.3390/biomedicines10050934
_version_ 1784714732069978112
author Berghäll, Elisabeth
Hultström, Michael
Frithiof, Robert
Lipcsey, Miklos
Hahn-Strömberg, Victoria
author_facet Berghäll, Elisabeth
Hultström, Michael
Frithiof, Robert
Lipcsey, Miklos
Hahn-Strömberg, Victoria
author_sort Berghäll, Elisabeth
collection PubMed
description Background: Severe coronavirus disease 2019 (COVID-19) causes a strong inflammatory response. To obtain an overview of inflammatory mediators and effector cells, we studied 25 intensive-care-unit patients during the timeframe after off-label chloroquine treatment and before an introduction of immunomodulatory drugs. Material and methods: Blood samples were weekly examined with flow cytometry (FCM) for surface and intracytoplasmic markers, cytokine assays were analyzed for circulating interleukins (ILs), and blood smears were evaluated for morphological changes. Samples from healthy volunteers were used for comparison. Organ function data and 30-day mortality were obtained from medical records. Results: Compared to that of the healthy control group, the expression levels of leukocyte surface markers, i.e., the cluster of differentiation (CD) markers CD2, CD4, CD8, CD158d, CD25, CD127, and CD19, were lower (p < 0.001), while those of leukocytes expressing CD33 were increased (p < 0.05). An aberrant expression of CD158d on granulocytes was found on parts of the granulocyte population. The expression levels of intracellular tumor necrosis factor alpha (TNFα) and IL-1 receptor type 2 in leukocytes were lower (p < 0.001), and the plasma levels of TNFα, IL-2, IL-6, IL-8, IL-10 (p < 0.001), interferon gamma (IFNγ) (p < 0.01), and granulocyte-macrophage colony-stimulating factor (GM-CSF) (p < 0.05) were higher in patients with severe COVID-19 than in the control group. The expression levels of CD33+ leukocytes and circulating IL-6 were higher (p < 0.05) among patients with arterial oxygen partial pressure-to-fractional inspired oxygen (PaO(2)/FiO(2)) ratios below 13.3 kPa compared to in the remaining patients. The expression levels of TNFα, IL-2, IL-4, IL-6, IL-8, and IL-10 were higher in patients treated with continuous renal replacement therapy (CRRT) (p < 0.05), and the levels of the maximum plasma creatinine and TNFα Spearman’s rank-order correlation coefficient (rho = 0.51, p < 0.05) and IL-8 (rho = 0.44, p < 0.05) correlated. Blood smears revealed neutrophil dysplasia with pseudo-Pelger forms being most common. Conclusion: These findings suggest that patients with severe COVID-19, in addition to augmented ILs, lymphopenia, and increased granulocytes, also had effects on the bone marrow.
format Online
Article
Text
id pubmed-9138896
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-91388962022-05-28 The Evolution of Blood Cell Phenotypes, Intracellular and Plasma Cytokines and Morphological Changes in Critically Ill COVID-19 Patients Berghäll, Elisabeth Hultström, Michael Frithiof, Robert Lipcsey, Miklos Hahn-Strömberg, Victoria Biomedicines Article Background: Severe coronavirus disease 2019 (COVID-19) causes a strong inflammatory response. To obtain an overview of inflammatory mediators and effector cells, we studied 25 intensive-care-unit patients during the timeframe after off-label chloroquine treatment and before an introduction of immunomodulatory drugs. Material and methods: Blood samples were weekly examined with flow cytometry (FCM) for surface and intracytoplasmic markers, cytokine assays were analyzed for circulating interleukins (ILs), and blood smears were evaluated for morphological changes. Samples from healthy volunteers were used for comparison. Organ function data and 30-day mortality were obtained from medical records. Results: Compared to that of the healthy control group, the expression levels of leukocyte surface markers, i.e., the cluster of differentiation (CD) markers CD2, CD4, CD8, CD158d, CD25, CD127, and CD19, were lower (p < 0.001), while those of leukocytes expressing CD33 were increased (p < 0.05). An aberrant expression of CD158d on granulocytes was found on parts of the granulocyte population. The expression levels of intracellular tumor necrosis factor alpha (TNFα) and IL-1 receptor type 2 in leukocytes were lower (p < 0.001), and the plasma levels of TNFα, IL-2, IL-6, IL-8, IL-10 (p < 0.001), interferon gamma (IFNγ) (p < 0.01), and granulocyte-macrophage colony-stimulating factor (GM-CSF) (p < 0.05) were higher in patients with severe COVID-19 than in the control group. The expression levels of CD33+ leukocytes and circulating IL-6 were higher (p < 0.05) among patients with arterial oxygen partial pressure-to-fractional inspired oxygen (PaO(2)/FiO(2)) ratios below 13.3 kPa compared to in the remaining patients. The expression levels of TNFα, IL-2, IL-4, IL-6, IL-8, and IL-10 were higher in patients treated with continuous renal replacement therapy (CRRT) (p < 0.05), and the levels of the maximum plasma creatinine and TNFα Spearman’s rank-order correlation coefficient (rho = 0.51, p < 0.05) and IL-8 (rho = 0.44, p < 0.05) correlated. Blood smears revealed neutrophil dysplasia with pseudo-Pelger forms being most common. Conclusion: These findings suggest that patients with severe COVID-19, in addition to augmented ILs, lymphopenia, and increased granulocytes, also had effects on the bone marrow. MDPI 2022-04-19 /pmc/articles/PMC9138896/ /pubmed/35625671 http://dx.doi.org/10.3390/biomedicines10050934 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Berghäll, Elisabeth
Hultström, Michael
Frithiof, Robert
Lipcsey, Miklos
Hahn-Strömberg, Victoria
The Evolution of Blood Cell Phenotypes, Intracellular and Plasma Cytokines and Morphological Changes in Critically Ill COVID-19 Patients
title The Evolution of Blood Cell Phenotypes, Intracellular and Plasma Cytokines and Morphological Changes in Critically Ill COVID-19 Patients
title_full The Evolution of Blood Cell Phenotypes, Intracellular and Plasma Cytokines and Morphological Changes in Critically Ill COVID-19 Patients
title_fullStr The Evolution of Blood Cell Phenotypes, Intracellular and Plasma Cytokines and Morphological Changes in Critically Ill COVID-19 Patients
title_full_unstemmed The Evolution of Blood Cell Phenotypes, Intracellular and Plasma Cytokines and Morphological Changes in Critically Ill COVID-19 Patients
title_short The Evolution of Blood Cell Phenotypes, Intracellular and Plasma Cytokines and Morphological Changes in Critically Ill COVID-19 Patients
title_sort evolution of blood cell phenotypes, intracellular and plasma cytokines and morphological changes in critically ill covid-19 patients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9138896/
https://www.ncbi.nlm.nih.gov/pubmed/35625671
http://dx.doi.org/10.3390/biomedicines10050934
work_keys_str_mv AT berghallelisabeth theevolutionofbloodcellphenotypesintracellularandplasmacytokinesandmorphologicalchangesincriticallyillcovid19patients
AT hultstrommichael theevolutionofbloodcellphenotypesintracellularandplasmacytokinesandmorphologicalchangesincriticallyillcovid19patients
AT frithiofrobert theevolutionofbloodcellphenotypesintracellularandplasmacytokinesandmorphologicalchangesincriticallyillcovid19patients
AT lipcseymiklos theevolutionofbloodcellphenotypesintracellularandplasmacytokinesandmorphologicalchangesincriticallyillcovid19patients
AT hahnstrombergvictoria theevolutionofbloodcellphenotypesintracellularandplasmacytokinesandmorphologicalchangesincriticallyillcovid19patients
AT berghallelisabeth evolutionofbloodcellphenotypesintracellularandplasmacytokinesandmorphologicalchangesincriticallyillcovid19patients
AT hultstrommichael evolutionofbloodcellphenotypesintracellularandplasmacytokinesandmorphologicalchangesincriticallyillcovid19patients
AT frithiofrobert evolutionofbloodcellphenotypesintracellularandplasmacytokinesandmorphologicalchangesincriticallyillcovid19patients
AT lipcseymiklos evolutionofbloodcellphenotypesintracellularandplasmacytokinesandmorphologicalchangesincriticallyillcovid19patients
AT hahnstrombergvictoria evolutionofbloodcellphenotypesintracellularandplasmacytokinesandmorphologicalchangesincriticallyillcovid19patients